SIX: OBSN

Company Deals

ObsEva SA Regains Full Rights to Nolasiban After Terminating Yuyuan Biological License Deal

Fineline Cube Jul 18, 2023

Swiss biopharmaceutical company ObsEva SA (SIX: OBSN) has announced that it has regained full rights...

Company Drug

Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint

Company Medical Device

Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures

Company Deals

Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes

Company Drug

Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod